EE04852B1 - C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel - Google Patents

C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel

Info

Publication number
EE04852B1
EE04852B1 EEP200100437A EEP200100437A EE04852B1 EE 04852 B1 EE04852 B1 EE 04852B1 EE P200100437 A EEP200100437 A EE P200100437A EE P200100437 A EEP200100437 A EE P200100437A EE 04852 B1 EE04852 B1 EE 04852B1
Authority
EE
Estonia
Prior art keywords
epothiolones
cancerous
modified
treatment
making
Prior art date
Application number
EEP200100437A
Other languages
English (en)
Estonian (et)
Inventor
Hoefle Gerhard
Glaser Nicole
Leibold Thomas
D. Vite Gregory
Kim Soong-Hoon
Original Assignee
Gesellschaft Fuer Biotechnologische Forschung Mbh
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999107588 external-priority patent/DE19907588A1/de
Priority claimed from DE1999130111 external-priority patent/DE19930111A1/de
Application filed by Gesellschaft Fuer Biotechnologische Forschung Mbh, Bristol-Myers Squibb Company filed Critical Gesellschaft Fuer Biotechnologische Forschung Mbh
Publication of EE200100437A publication Critical patent/EE200100437A/xx
Publication of EE04852B1 publication Critical patent/EE04852B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
EEP200100437A 1999-02-22 2000-02-17 C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel EE04852B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1999107588 DE19907588A1 (de) 1999-02-22 1999-02-22 C-21 Modifizierte Epothilone
DE1999130111 DE19930111A1 (de) 1999-07-01 1999-07-01 C-21 Modifizierte Epothilone
PCT/US2000/004068 WO2000050423A1 (en) 1999-02-22 2000-02-17 C-21 modified epothilones

Publications (2)

Publication Number Publication Date
EE200100437A EE200100437A (et) 2002-12-16
EE04852B1 true EE04852B1 (et) 2007-06-15

Family

ID=26051995

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100437A EE04852B1 (et) 1999-02-22 2000-02-17 C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel

Country Status (37)

Country Link
US (1) US6262094B1 (de)
EP (1) EP1157023B1 (de)
JP (1) JP4598957B2 (de)
KR (1) KR100685336B1 (de)
CN (1) CN1205208C (de)
AR (1) AR028815A1 (de)
AT (1) ATE254615T1 (de)
AU (1) AU771089B2 (de)
BG (1) BG64987B1 (de)
BR (1) BR0008379A (de)
CA (1) CA2360452C (de)
CO (1) CO5140093A1 (de)
CZ (1) CZ301498B6 (de)
DE (1) DE60006649T2 (de)
DK (1) DK1157023T3 (de)
EE (1) EE04852B1 (de)
ES (1) ES2209831T3 (de)
GE (1) GEP20033067B (de)
HK (1) HK1038923B (de)
HU (1) HUP0200076A3 (de)
ID (1) ID29829A (de)
IL (1) IL144501A0 (de)
LT (1) LT4944B (de)
LV (1) LV12755B (de)
MX (1) MXPA01008374A (de)
MY (1) MY120601A (de)
NO (1) NO320806B1 (de)
NZ (1) NZ513629A (de)
PE (1) PE20001546A1 (de)
PL (1) PL212545B1 (de)
PT (1) PT1157023E (de)
RU (1) RU2253652C2 (de)
SK (1) SK287200B6 (de)
TR (1) TR200102401T2 (de)
TW (1) TWI270546B (de)
UY (1) UY26024A1 (de)
WO (1) WO2000050423A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022461A1 (de) * 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP4579351B2 (ja) * 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
GB9810659D0 (en) * 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6589968B2 (en) * 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
HUP0302905A3 (en) 2000-09-22 2006-05-29 Biotechnolog Forschung Gmbh Triazolo-epothilone-analogs, process for their preparation and pharmaceutical compositions containing them
CA2425828A1 (en) * 2000-10-13 2002-04-18 The University Of Mississippi Synthesis of epothilones and related analogs
JP2004521122A (ja) * 2001-01-25 2004-07-15 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン類似体の非経口製剤
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
CA2438610A1 (en) 2001-02-20 2002-08-29 Francis Y. F. Lee Treatment of refractory tumors using epothilone derivatives
MXPA03007423A (es) * 2001-02-20 2003-11-18 Bristol Myers Squibb Co Derivados de epotilona para tratamiento de tumores refractarios.
CZ305799B6 (cs) * 2001-03-14 2016-03-23 Bristol-Myers Squibb Company Kombinace analogů epothilonu a chemoterapeutických činidel pro léčení proliferačních nemocí
TWI341728B (en) * 2002-01-14 2011-05-11 Novartis Ag Combinations comprising epothilones and anti-metabolites
TW200303202A (en) 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
US6900331B2 (en) * 2002-03-01 2005-05-31 University Of Notre Dame Derivatives of epothilone B and D and synthesis thereof
SI1485090T1 (sl) * 2002-03-08 2008-06-30 Novartis Ag Kombinacija vključujoča derivat epotilona in imidazotetrazinon
IL163774A0 (en) * 2002-03-08 2005-12-18 Univ Newcastle Combinations comprising epothilone derivatives andalkylating agents
WO2003077903A1 (en) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
ATE452896T1 (de) 2002-03-12 2010-01-15 Bristol Myers Squibb Co C3-cyanoepothilonderivate
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
DE60328772D1 (de) * 2002-05-01 2009-09-24 Novartis Ag Epothilonderivat zur behandlung von hepatoma und anderen krebserkrankungen
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2496477C (en) 2002-08-23 2012-10-16 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO2004026254A2 (en) 2002-09-23 2004-04-01 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
JP2006504745A (ja) * 2002-10-09 2006-02-09 コーザン バイオサイエンシス インコーポレイテッド エポｄ及び５−ｆｕ／ゲムシタビン
ATE479667T1 (de) 2003-02-06 2010-09-15 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1559447A1 (de) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verwendung von Epothilonen zur Behandlung von neuronalen Konnektivitätsdefekten wie zum Beispiel Schizophrenie und Autismus
GB0405898D0 (en) 2004-03-16 2004-04-21 Novartis Ag Organic compounds
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
CA2588400A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising ixabepilone, and preparation thereof
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
WO2007062288A2 (en) * 2005-11-22 2007-05-31 The Scripps Research Institute Chemical synthesis of a highly potent epothilone
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
MY159563A (en) 2006-05-16 2017-01-13 Pharmascience Inc Iap bir domain binding compounds
WO2008109075A2 (en) * 2007-03-05 2008-09-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
CN101754969A (zh) * 2007-05-25 2010-06-23 百时美施贵宝公司 制备埃坡霉素化合物和类似物的方法
CN101909693A (zh) 2008-01-08 2010-12-08 百时美施贵宝公司 用于治疗增殖性疾病的抗-ctla4抗体与微管蛋白调节剂的组合
EA021758B1 (ru) * 2008-04-24 2015-08-31 Бристол-Маерс Сквибб Компани Способ лечения болезни альцгеймера
MX2010012579A (es) * 2008-05-29 2010-12-20 Squibb Bristol Myers Co Metodos para predecir respuesta de pacientes a modulacion de la via co-estimuladora.
US8119129B2 (en) * 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
CN102822200A (zh) 2009-07-20 2012-12-12 百时美施贵宝公司 对增殖性疾病进行协同性治疗的抗ctla-4抗体与各种治疗方案的组合
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
PT2496567T (pt) 2009-11-05 2017-11-15 Rhizen Pharmaceuticals S A Novos moduladores de quinase benzopiran
KR20120140658A (ko) 2010-02-12 2012-12-31 파마사이언스 인크. Ｉａｐ ｂｉｒ 도메인 결합 화합물
CA2798080C (en) 2010-05-17 2020-08-25 Incozen Therapeutics Pvt. Ltd. 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
EP2571577A1 (de) 2010-05-17 2013-03-27 Bristol-Myers Squibb Company Verbesserte immuntherapeutische dosierpläne und kombinationen daraus
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease
KR101992311B1 (ko) 2011-05-04 2019-09-27 리젠 파마슈티컬스 소시에떼 아노님 단백질 키나아제의 조절제로서 신규한 화합물
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
AP3908A (en) 2012-03-30 2016-11-24 Rhizen Pharmaceuticals Sa Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases
CN104768962B (zh) 2012-11-17 2017-04-05 北京市丰硕维康技术开发有限责任公司 离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
CA2905509A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
US20160264670A1 (en) 2013-11-06 2016-09-15 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
MX2017007097A (es) 2014-12-04 2017-09-05 Bristol Myers Squibb Co Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
ES2886657T3 (es) 2015-06-29 2021-12-20 Bristol Myers Squibb Co Regímenes de dosificación inmunoterapéutica que comprenden pomalidomida y un anticuerpo anti-CS1 para el tratamiento de cáncer
CN105153177B (zh) * 2015-09-28 2017-08-08 湖南大学 呋喃并色满肟烯/炔丙基醚及其制备方法与应用
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE75883C (de) W. schulte in Siegen und F. A. SAPP in Hillnhütten, Kreis Siegen Ofen zur Erzeugung von Cyanammonium
DE301115C (de)
GB8909737D0 (en) * 1989-04-27 1989-06-14 Shell Int Research Thiazole derivatives
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
JP4183099B2 (ja) 1995-11-17 2008-11-19 ゲゼルシャフト・フュア・ビオテヒノロジッシェ・フォルシュング・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） エポチロンｃおよびｄ、製造法ならびに組成物
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
WO1998022461A1 (de) * 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
DE19707303B4 (de) 1997-02-11 2006-05-11 Mitteldeutsches Bitumenwerk Gmbh Verfahren zur Gewinnung von Mikrowachsen, Paraffinen und Ölen aus Altkunststoffen oder Altkunststoffgemischen
NZ337195A (en) 1997-02-25 2001-05-25 Biotechnolog Forschung Gmbh Epothilones with a modified side chain
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
WO1998047891A1 (de) 1997-04-18 1998-10-29 Studiengesellschaft Kohle Mbh Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
ATE224882T1 (de) 1997-07-16 2002-10-15 Schering Ag Thiazolderivate, verfahren zur herstellung und verwendung
DK1005465T3 (da) 1997-08-09 2007-11-05 Bayer Schering Pharma Ag Nye epothilon-derivater, fremgangsmåde til fremstilling heraf og deres farmaceutiske anvendelse
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
HK1040739A1 (zh) * 1998-12-23 2002-06-21 Bristol-Myers Squibb Company 微生物转形方法，用以制造epothilone

Also Published As

Publication number Publication date
BG64987B1 (bg) 2006-11-30
MXPA01008374A (es) 2003-06-06
CZ301498B6 (cs) 2010-03-24
EP1157023B1 (de) 2003-11-19
US6262094B1 (en) 2001-07-17
HK1038923A1 (en) 2002-04-04
AR028815A1 (es) 2003-05-28
TWI270546B (en) 2007-01-11
IL144501A0 (en) 2002-05-23
ID29829A (id) 2001-10-11
DK1157023T3 (da) 2004-03-29
HK1038923B (en) 2004-03-19
KR100685336B1 (ko) 2007-02-23
WO2000050423A1 (en) 2000-08-31
PT1157023E (pt) 2004-03-31
JP2002537395A (ja) 2002-11-05
GEP20033067B (en) 2003-09-25
CA2360452C (en) 2011-07-26
CN1205208C (zh) 2005-06-08
BG105830A (en) 2002-03-29
RU2253652C2 (ru) 2005-06-10
DE60006649D1 (de) 2003-12-24
DE60006649T2 (de) 2004-09-30
KR20010102199A (ko) 2001-11-15
EE200100437A (et) 2002-12-16
CN1341114A (zh) 2002-03-20
NZ513629A (en) 2004-01-30
UY26024A1 (es) 2000-09-29
LV12755B (lv) 2002-04-20
PL350179A1 (en) 2002-11-18
TR200102401T2 (tr) 2001-12-21
ATE254615T1 (de) 2003-12-15
NO20014017D0 (no) 2001-08-17
BR0008379A (pt) 2002-09-24
SK287200B6 (sk) 2010-03-08
NO320806B1 (no) 2006-01-30
NO20014017L (no) 2001-10-17
EP1157023A1 (de) 2001-11-28
MY120601A (en) 2005-11-30
CO5140093A1 (es) 2002-03-22
LV12755A (en) 2001-11-20
JP4598957B2 (ja) 2010-12-15
CA2360452A1 (en) 2000-08-31
PE20001546A1 (es) 2001-03-18
HUP0200076A3 (en) 2003-01-28
AU3234800A (en) 2000-09-14
HUP0200076A2 (hu) 2002-12-28
SK10782001A3 (sk) 2002-03-05
LT2001086A (en) 2002-04-25
AU771089B2 (en) 2004-03-11
CZ20012991A3 (cs) 2002-01-16
PL212545B1 (pl) 2012-10-31
ES2209831T3 (es) 2004-07-01
LT4944B (lt) 2002-08-26

Similar Documents

Publication Publication Date Title
EE04852B1 (et) C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
IL197903A (en) A pharmacovigilance containing riavirus to treat cell culture disorders and its kit
IL151946A0 (en) 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
EE200200118A (et) Terapeutilised kinasoliini derivaadid, nende valmistamise meetod ning kasutamine
HUP0104867A3 (en) Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use
AR028426A1 (es) Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfunsion cognitiva en un mamifero
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
EE05109B1 (et) Sulfoonamiidi derivaadid, nende kasutamine meditsiinis ning meetod nende valmistamiseks
EE200100391A (et) Peptidüül-heterotsüklilised ketoonid, nende kasutamine ja farmatseutiline kompositsioon
DE69941996D1 (de) Pharmazeutische zusammenstellung zur verwendung in notbehandlungen und dessen herstellungsverfahren
WO2001049703A3 (en) Substituted sapogenins and their use
EE200100470A (et) Püridopüranoasepiini derivaadid, nende valmistamine ja terapeutiline kasutamine
WO2001028494A3 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
MY138883A (en) Use of asiatic acid for treatment of cencer
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
EE04490B1 (et) Ühend, selle valmistamise meetod ning kasutamine meditsiinis
EE05099B1 (et) Bradkardiaalsete toimeainete kasutamine hpertroofiaga seotud mokardiaalsete haiguste ravimiseks ja ravimikombinatsioonid
AU2001270484A1 (en) Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
EE200300504A (et) 3,7-diasabitsüklo[3.3.1]preparaadid, nende valmistamise meetod ja nimetatud preparaatide kasutaminesüdame arütmiate profülaktikas või ravis
EE200000333A (et) Eesnäärmevähi ravis kasutatav konjugaat ning farmatseutiline kompositsioon ja selle valmistamismeetod
DE69939075D1 (de) Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
GB9923078D0 (en) Sapogenin derivatives and their use
EE200400074A (et) Koostised ning nende kasutamine proliferatiivsetehaiguste raviks
EE9800451A (et) Uued imidasotriasolopürimidiinid, nende valmistamismeetod ja kasutamine ravimainetena

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231